



PSORIASIS

A CASE OF PSORIASIS VULGARIS TREATED WITH SECUKINUMAB

Wahyu Lestari Lestari⁽¹⁾ - Mimi Maulida Maulida⁽¹⁾ - Nanda Earlia Earlia⁽¹⁾ - Sitti Hajar Hajar⁽¹⁾ - Fitria Fitria⁽¹⁾

Syiah Kuala University, Department Of Dermatology And Venereology Dr. Zainoel Abidin Hospital/ Universitas Syiah Kuala, Banda Aceh, Indonesia, Banda Aceh, Indonesia⁽¹⁾

Background: Psoriasis vulgaris is a chronic inflammatory skin disease. its characterized by plaque erythematous with thick scales. Adequate therapy can prevent the disease and exacerbation of comorbidity. Secukinumab (anti IL-17) is biologic agents used to treat moderate to severe plaque type psoriasis.

Case report: We present the case of a 36- year – old female with manifestation of plaque erythematous with thick scales on the scalp, trunk, both of arms and legs. The Psoriasis Area and Severity Index score was 32,4 and The Daily Living Questionnaire's (DLQ1) score was 21. Histopathologic examination revealed feature of akantosis, prolongation of rete ridge, parakeratosis, thinning of supra papilla dermis, microabcess Munro. The patient was treated with topical steroid, emmolients, phototherapy UVB, and metothrexate, but there was no improvement after treatment was given. We decided to administered secukinumab treatment 300 mg (0-4 weeks) and emmolients combinations. There was improvement and satisfactory compliance with this choice of treatment.

Conclusion: treatment with secukinumab is one of the therapies for patiets with psoriasis vulgaris who resistant with topical or oral therapy. The Effectiveness is visible after 4 weeks of therapy with decreased in PASI score up to 75% and DLQ1 score was 3. Clinical efficacy, cost, safety, convenience and management of comorbid diseases are important before we use secukinumab.

Keywords : psoriasis vulgaris, secukinumab, biologic agents

